First line immunotherapy combination fails to improve overall survival in lung cancer

(European Society for Medical Oncology) First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news